Researchers looked specifically at head-to-head randomized clinical trials of next-in-class cancer drugs against existing agents in the same class. Less than one-quarter of next-in-class cancer drugs ...

In 22.2% of trials, there was a survival benefit with the next-in-class agent. Less than one-quarter of next-in-class cancer drugs demonstrated a survival benefit over existing in-class agents in head ...

The drug is not considered a cure, but results from clinical trials point to major advancement for a devastating cancer ...

Scientists could reshape cancer treatment by helping powerful drugs work better in the body by exploiting a surface protein called CD36 that helps pull substances into cells. This dramatically ...

A new cancer drug candidate has demonstrated the ability to block tumor growth without triggering a common and debilitating side effect. The compound was developed by Lawrence Livermore National ...